The Library

New trends for metal complexes with anticancer activity

Tools

Bruijnincx, Pieter C. A. and Sadler, P. J.. (2008) New trends for metal complexes with anticancer activity. Current Opinion in Chemical Biology, Vol.12 (No.2). pp. 197-206. ISSN 1367-5931

PDF
WRAP_Sadler_New_Trends_PMID_18155674_COCB_WRAP.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (754Kb)

Official URL: http://dx.doi.org/10.1016/j.cbpa.2007.11.013

Abstract

Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is, however, severely limited by its toxic side-effects. This has spurred chemists to employ different strategies in the development of new metal-based anticancer agents with different mechanisms of action. Recent trends in the field are discussed in this review. These include the more selective delivery and/or activation of cisplatin-related prodrugs and the discovery of new non-covalent interactions with the classical target, DNA. The use of the metal as scaffold rather than reactive centre and the departure from the cisplatin paradigm of activity towards a more targeted, cancer cell-specific approach, a major trend, are discussed as well. All this, together with the observation that some of the new drugs are organometallic complexes, illustrates that exciting times lie ahead for those interested in ‘metals in medicine.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Cisplatin -- Research, Metals in medicine, Organometallic compounds, Cancer -- Treatment, Metal ions -- Research
Journal or Publication Title:	Current Opinion in Chemical Biology
Publisher:	Elsevier Ltd.
ISSN:	1367-5931
Date:	April 2008
Volume:	Vol.12
Number:	No.2
Number of Pages:	10
Page Range:	pp. 197-206
Identification Number:	10.1016/j.cbpa.2007.11.013
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	Royal Society (Great Britain), Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (Great Britain) (BBSRC), Nederlandse Organisatie voor Wetenschappelijk Onderzoek [Netherlands Organisation for Scientific Research] (NWO), Wellcome Trust (London, England), European Cooperation in the Field of Scientific and Technical Research (Organization) (COST), Scottish Enterprise (SE), Oncosense Ltd.
References:	Papers of particular interest, published within the annual period of review, have been highlighted as:  of special interest  of outstanding interest  1. Hambley TW: Developing new metal-based therapeutics: challenges and opportunities. Dalton Trans 2007:4929-4937. This recent perspective provides an excellent introduction to the present status of the field of medicinal inorganic chemistry and discusses the difficulties that are currently faced in the development of new metal-based therapeutics 2. Orvig C, Abrams MJ: Medicinal inorganic chemistry: introduction. Chem Rev 1999, 99:2201-2203. 3. Guo Z, Sadler PJ: Metals in Medicine. Angew Chem Int Ed 1999, 38:1512-1531. 4. Thompson KH, Orvig C: Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Dalton Trans 2006:761-764. 5. Jung Y, Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev 2007, 107:1387- 1407. 6. van Zutphen S, Reedijk J: Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. Coord Chem Rev 2005, 249:2845-2853. 7. Yang Z, Wang XY, Diao HJ, Zhang JF, Li HY, Sun HZ, Guo ZJ: Encapsulation of platinum anticancer drugs by apoferritin. Chem Commun 2007:3453-3455. 8. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, et al.: Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007, 11:431-445. 9. Hall MD, Mellor HR, Callaghan R, Hambley TW: Basis for design and development of platinum(IV) anticancer complexes. J Med Chem 2007, 50:3403-3411. 10. Barnes KR, Kutikov A, Lippard SJ: Synthesis, characterization, and cytotoxicity of a series of estrogentethered platinum(IV) complexes. Chem Biol 2004, 11:557-564. 11. Ang WH, Khalaila I, Allardyce CS, Juillerat-Jeanneret L, Dyson PJ: Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc 2005, 127:1382- 1383.  12. Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ: Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc 2007, 129:8438-8439. A dual strategy against platinum drug inactivation is presented by attaching a Pt(IV) prodrug to a carbon nanotube delivery system. The conjugate showed increased cellular uptake and displayed high cytotoxicity. The ability to attach other additional compounds to the platinated longboats provides an interesting opportunity for targeted delivery.  13. Bednarski PJ, Grunert R, Zielzki M, Wellner A, Mackay FS, Sadler PJ: Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem Biol 2006, 13:61-67. Photolabile platinum(IV) diazide complexes are nontoxic in the dark, but demonstrate good cytotoxicity upon irradiation with light against human bladder cancer cells. No crossresistance with cisplatin is observed. The photoactivation pathway does not rely on oxygen, unlike current photodynamic therapy. See also [14]. 14. Mackay FS, Woods JA, Moseley H, Ferguson J, Dawson A, Parsons S, Sadler PJ: A photoactivated transdiammine platinum complex as cytotoxic as cisplatin. Chem Eur J 2006, 12:3155-3161. 15. Heringova P, Woods J, Mackay FS, Kasparkova J, Sadler PJ, Brabec V: Transplatin is cytotoxic when photoactivated: Enhanced formation of DNA cross-links. J Med Chem 2006, 49:7792-7798. 16. Lutterman DA, Fu PKL, Turro C: cis-[Rh2(-O2CCH3)2(CH3CN)6]2+ as a photoactivated cisplatin analog. J Am Chem Soc 2006, 128:738-739. 17. Ang WH, Dyson PJ: Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy. Eur J Inorg Chem 2006:4003-4018. 18. Liu HK, Berners-Price SJ, Wang FY, Parkinson JA, Xu JJ, Bella J, Sadler PJ: Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex. Angew Chem Int Ed 2006, 45:8153- 8156.  19. Habtemariam A, Melchart M, Fernandez R, Parsons S, Oswald IDH, Parkin A, Fabbiani FPA, Davidson JE, Dawson A, Aird RE, et al.: Structure-Activity Relationships for Cytotoxic Ruthenium(II) Arene Complexes Containing N,N-, N,O-, and O,O-Chelating Ligands. J Med Chem 2006, 49:6858-6868. Systematic ligand variation resulted in organometallic ruthenium-arene complexes as cytotoxic as cisplatin and established a structure-activity relationship for cytotoxicity. No cross-resistance with cisplatin was observed . 20. Yan YK, Melchart M, Habtemariam A, Sadler PJ: Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem Commun 2005:4764-4776.  21. Peacock AFA, Parsons S, Sadler PJ: Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. J Am Chem Soc 2007, 129:3348- 3357. The aqueous and hydrolytic chemistry of osmium analogues of the half-sandwich ruthenium(II) complexes were studied by systematic variation of the chelating ligand on osmium. The rational control of chemical reactivity resulted in cytotoxic osmium-arene complexes. 22. Dyson PJ, Sava G: Metal-based antitumour drugs in the post genomic era. Dalton Trans 2006:1929-1933. 23. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK: Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology. Chem Rev 2006, 106:2224-2248. 24. Calderone V, Casini A, Mangani S, Messori L, Orioli PL: Structural investigation of cisplatin-protein interactions: Selective platination of His19 in a cuprozinc superoxide dismutase. Angew Chem Int Ed 2006, 45:1267-1269. 25. McNae IW, Fishburne K, Habtemariam A, Hunter TM, Melchart M, Wang FY, Walkinshaw MD, Sadler PJ: Half-sandwich arene ruthenium(II)-enzyme complex. Chem Commun 2004:1786-1787. 26. Casini A, Mastrobuoni G, Ang WH, Gabbiani C, Pieraccini G, Moneti G, Dyson PJ, Messori L: ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes. ChemMedChem 2007, 2:631-635. 27. Weidt SK, Mackay CL, Langridge-Smith PRR, Sadler PJ: Platination of superoxide dismutase with cisplatin: tracking the ammonia ligands using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS). Chem Commun 2007:1719-1721. 28. Reed JE, Arnal AA, Neidle S, Vilar R: Stabilization of G-quadruplex DNA and inhibition of telomerase activity by square-planar nickel(II) complexes. J Am Chem Soc 2006, 128:5992-5993.  29. Dixon IM, Lopez F, Tejera AM, Esteve JP, Blasco MA, Pratviel G, Meunier B: A G-quadruplex ligand with 10000-fold selectivity over duplex DNA. J Am Chem Soc 2007, 129:1502-1503. A metalloporphyrin is reported that shows both a very high affinity and an excellent selectivity for G-quadruplex DNA over GC-rich or AT-rich DNA.  30. Komeda S, Moulaei T, Woods KK, Chikuma M, Farrell NP, Williams LD: A third mode of DNA binding: Phosphate clamps by a polynuclear platinum complex. J Am Chem Soc 2006, 128:16092-16103. The polynuclear platinum complex TriplatinNC binds to DNA through specific hydrogen bonding interactions called phosphate clamps, presenting a new DNA binding mode. The modularity of TriplatinNC holds promise for the assembly of drugs that selectively bind to specific DNA forms. 31. Harris AL, Yang X, Hegmans A, Povirk L, Ryan JJ, Kelland L, Farrell NP: Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. Inorg Chem 2005, 44:9598-9600.  32. Oleksi A, Blanco AG, Boer R, Uson I, Aymami J, Rodger A, Hannon MJ, Coll M: Molecular recognition of a three-way DNA junction by a metallosupramolecular helicate. Angew Chem Int Ed 2006, 45:1227-1231. The crystal structure of a supramolecular cylinder with a palindromic hexanucleotide revealed a new DNA binding mode. The iron-containing triple helicate was found at the heart of a three-way DNA junction. 33. Hannon MJ: Supramolecular DNA recognition. Chem Soc Rev 2007, 36:280-295. 34. Pascu GI, Hotze ACG, Sanchez-Cano C, Kariuki BM, Hannon MJ: Dinuclear ruthenium(II) triple-stranded helicates: Luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines. Angew Chem Int Ed 2007, 46:4374-4378. 35. Hotze ACG, Kariuki BM, Hannon MJ: Dinuclear double-stranded metallosupramolecular ruthenium complexes: Potential anticancer drugs. Angew Chem Int Ed 2006, 45:4839-4842.  36. Meggers E, Atilla-Gokcumen GE, Bregman H, Maksimoska J, Mulcahy SP, Pagano N, Williams DS: Exploring chemical space with organometallics: Ruthenium complexes as protein kinase inhibitors. Synlett 2007:1177-1189. This account discusses the concept of exploration of chemical space with organometallic ruthenium complexes and gives an overview of the impressive results obtained by the Meggers group thus far. See also references [37] and [38]. 37. Bregman H, Carroll PJ, Meggers E: Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc 2006, 128:877-884. 38. Debreczeni JE, Bullock AN, Atilla GE, Williams DS, Bregman H, Knapp S, Meggers E: Ruthenium halfsandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed 2006, 45:1580-1585. 39. Smalley KSM, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, et al.: An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 2007, 67:209-217. 40. Urig S, Becker K: On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 2006, 16:452-465. 41. Urig S, Fritz-Wolf K, Reau R, Herold-Mende C, Toth K, Davioud-Charvet E, Becker K: Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. Angew Chem Int Ed 2006, 45:1881-1886. 42. Barnard PJ, Berners-Price SJ: Targeting the mitochondrial cell death pathway with gold compounds. Coord Chem Rev 2007, 251:1889-1902.  43. Sun RWY, Ma DL, Wong ELM, Che CM: Some use of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans 2007, 4884-4892. This perspective covers the recent contributions of the Che laboratory to the development of transition-metal-based anticancer complexes, including gold, platinum, ruthenium and iron complexes.  44. Wang Y, He QY, Che CM, Chiu JF: Proteomic characterization of the cytotoxic mechanism of gold(III) porphyrin 1a, a potential anticancer drug. Proteomics 2006, 6:131-142. A functional proteomics study on the cytotoxic mechanism of a gold(III) porphyrin anticancer drug was conducted to identify the proteins involved in apoptosis pathways. Multiple factors were identified, suggestive of mitochondria being centrally involved in cell death. 45. Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D, Dou QP: A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res 2006, 66:10478-10486. 46. Ott I, Schmidt K, Kircher B, Schumacher P, Wiglenda T, Gust R: Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: Studies on the mode of drug action. J Med Chem 2005, 48:622-629. 47. Failes TW, Cullinane C, Diakos CI, Yamamoto N, Lyons JG, Hambley TW: Studies of a cobalt(III) complex of the MMP inhibitor marimastat: A potential hypoxia-activated prodrug. Chem Eur J 2007, 13:2974-2982.  48. Bergamo A, Sava G: Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans 2007:1267-1272. The authors argue a case for a change in strategy for the development of new metallotherapeutics. Metastasis is identified as the primary target for drug therapy. See also reference [22]. 49. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ: In Vitro and in Vivo Evaluation of Ruthenium(II)-Arene PTA Complexes. J Med Chem 2005, 48:4161-4171. 50. Schatzschneider U, Metzler-Nolte N: New Principles in Medicinal Organometallic Chemistry. Angew Chem Int Ed 2006, 45:1504-1507.  51. Hillard E, Vessieres A, Thouin L, Jaouen G, Amatore C: Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. Angew Chem Int Ed 2006, 45:285-290. Electrochemical studies on a series of ferrocifen-type complexes revealed a structure-activity relationship and thus established minimal structural requirements for cytotoxic effect. 52. James P, Neudorfl J, Eissmann M, Jesse P, Prokop A, Schmalz HG: Enantioselective synthesis of ferrocenyl nucleoside analogues with apoptosis-inducing activity. Org Lett 2006, 8:2763-2766. 53. Schlawe D, Majdalani A, Velcicky J, Hessler E, Wieder T, Prokop A, Schmalz HG: Iron-containing nucleoside analogues with pronounced apoptosis-inducing activity. Angew Chem Int Ed 2004, 43:1731-1734.  54. Noor F, Wustholz A, Kinscherf R, Metzler-Nolte N: A cobaltocenium-peptide bioconjugate shows enhanced cellular uptake and directed nuclear delivery. Angew Chem Int Ed 2005, 44:2429-2432. Attaching a nuclear localization signal peptide to a cobaltocenium group resulted in significant accumulation of the conjugate in the nucleus of HepG2 cells. In addition to the peptide-mediated nuclear delivery, a metal-enhanced cellular uptake was observed as the organometallic group was essential for active endocytosis.
URI:	http://wrap.warwick.ac.uk/id/eprint/3360